PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer

PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer

PIP5K1α has emerged as a promising drug target for the treatment of castration-resistant prostate cancer (CRPC), as it acts upstream of the PI3K/AKT signaling pathway to promote prostate cancer (PCa) growth, survival and invasion. However, little is known of the molecular actions of PIP5K1α in this...

Full description

Bibliographic Details
Main Authors: Tianyan Wang, Martuza Sarwar, Jonathan B Whitchurch, Hilary M Collins, Tami Green, Julius Semenas, Amjad Ali, Christopher J Roberts, Ryan D Morris, Madlen Hubert, Sa Chen, Zahra El-Schich, Anette G Wingren, Thomas Grundström, Richard Lundmark, Nigel P Mongan, Lena Gunhaga, David M Heery, Jenny L Persson
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
castration-resistant prostate cancer (CRPC)
phosphatidylinositol 4-phosphate 5 kinase (PIP5K1α)
matrix metalloproteinases 9 (MMP9) PIP5K1α
targeted therapy
androgen receptor (AR)
cyclin-dependent kinase (CDK)
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2022.798590/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2022.798590/full

Similar Items